132 search results
Primary tabs
- Cochrane Evidence (active tab)
- Resources
- Handbooks & Manuals
- Training & Workshops
- News
- All Cochrane sites
-
UpdatedCochrane EvidencePublished 18 Jul 2017
Felbamate as an add-on therapy for refractory partial epilepsy
Review question This review aimed to assess whether felbamate has an impact on people with refractory partial-onset epilepsy when used with other antiepileptic drugs. Background Up to 30% people with epilepsy still suffer epileptic seizures despite the use of multiple treatments. Felbamate is a second-generation antiepileptic drug. However, it is ... -
UpdatedCochrane EvidencePublished 18 Jul 2017
Electrical stimulation through implanted electrodes in contact with the brain to treat drug-resistant epilepsy
Background Despite many antiepileptic drugs being available, about 30% of epilepsy patients are not seizure-free. Electrical stimulation through implanted electrodes in contact with the brain (i.e. intracranial electrical stimulation, referring to 'deep brain stimulation' and 'cortical brain stimulation') has been proposed as an alternative treatment ... -
NewCochrane EvidencePublished 12 Jul 2017
Medications for daytime sleepiness in individuals with idiopathic hypersomnia
Protocol: To assess the effects of medications for daytime sleepiness and related symptoms in individuals with idiopathic hypersomnia, and in particular whether medications may: reduce subjective measures of sleepiness; reduce objective measures of sleepiness; reduce symptoms of cognitive dysfunction; improve quality of life; and be associated ... -
UpdatedCochrane EvidencePublished 4 Jul 2017
Intravenous immunoglobulins for epilepsy
Background Epilepsy is a disorder where recurrent seizures are caused by abnormal electrical discharges in the brain. People with epilepsy may present with various types of immunological abnormalities. Most seizures can be controlled by antiepileptic drugs, but sometimes seizures develop which are resistant to these drugs. People may require other ... -
NewCochrane EvidencePublished 29 Jun 2017
Antiepileptic drug monotherapy (single drug treatment) for epilepsy
Background Epilepsy is a common neurological disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied two types of epileptic seizures in this review: partial seizures that start in one area of the brain, and generalised onset tonic-clonic seizures that start in both cerebral hemispheres simultaneously. For ... -
NewCochrane EvidencePublished 28 Jun 2017
Gabapentin monotherapy for epilepsy
Protocol: To assess the effects of gabapentin monotherapy for people with epileptic partial seizures with and without secondary generalisation. -
Cochrane EvidencePublished 18 May 2017
Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy
Background Severe myoclonic epilepsy in infants (SMEI), also known as Dravet syndrome, is a rare, drug-resistant form of epilepsy, for which stiripentol (STP) has been recently licensed for treatment when given in combination with other antiepileptic drugs. In this review, we evaluated the efficacy and tolerability of STP and other antiepileptic drugs ... -
TitlePublished 7 May 2017
Stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy
Epilepsy Group Victoria Walter Title Wednesday, May 3, 2017 ... -
Cochrane EvidencePublished 23 Apr 2017
Topiramate monotherapy for juvenile myoclonic epilepsy
Background Juvenile myoclonic epilepsy (JME) is characterized by involuntary (uncontrolled) twitching of muscles in shoulders and arms after awakening, often starting in childhood. Study characteristics We searched scientific databases for clinical trials comparing the antiepileptic drug, topiramate, with placebo (a pretend treatment) or another ... -
TitlePublished 5 Mar 2017
Clonazepam monotherapy for treating people with epilepsy
Epilepsy Group Francesco Brigo Title Thursday, March 2, 2017 ...
